{"disease":{"id":"non-small-cell-lung-cancer-small-cell-lung-cancer","name":"non small cell lung cancer small cell lung cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06255197","title":"Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04056247","title":"Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT02194738","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03505515","title":"Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":6205,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05254119","title":"DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Mahmut Gumus","has_results":false},{"nct_id":"NCT02728596","title":"S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3665,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT03782207","title":"A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2756,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02146170","title":"Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04501497","title":"Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)","phase":"","overall_status":"COMPLETED","enrollment_count":1221,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT04180176","title":"Prospective Clinicogenomic Program","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT07485166","title":"Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":810,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04613596","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":806,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT04644068","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":702,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03533127","title":"A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":648,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT01802632","title":"AZD9291 First Time In Patients Ascending Dose Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":603,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT00585195","title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07472647","title":"SYS6090 Combination Therapy in Advanced Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":596,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04205812","title":"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":583,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02409342","title":"A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06962449","title":"Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT07150598","title":"Immune-Marker Platform for Patients With Advanced Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT04818983","title":"The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)","phase":"","overall_status":"COMPLETED","enrollment_count":470,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT05983432","title":"Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT04623775","title":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":468,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04685135","title":"Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":453,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":true},{"nct_id":"NCT05183932","title":"Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":446,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05429866","title":"Immunological Variables Associated to ICI Toxicity in Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":441,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT06881784","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06885424","title":"A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT05607550","title":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":398,"lead_sponsor_name":"ArriVent BioPharma, Inc.","has_results":false},{"nct_id":"NCT06416410","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"Allist Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02193282","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":390,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07070518","title":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT03774732","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":327,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07491211","title":"Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT04697446","title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT04619004","title":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":277,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT05014815","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT05652868","title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Mythic Therapeutics","has_results":false},{"nct_id":"NCT06775002","title":"SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":223,"lead_sponsor_name":"Fuzhou General Hospital","has_results":false},{"nct_id":"NCT02562027","title":"SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":217,"lead_sponsor_name":"Washington University School of Medicine","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}